Key data reveals for the small players
Praxis, Proqr and Nordic Nanovector are awaiting important data.
Does amount matter when it comes to a biotech IPO?
Biontech and ADC Therapeutics are both heading towards substantial flotations, but it is hard to find evidence that bigger does better.
Asco 2019 event analyser – low-key meeting belies some huge stock moves
Mirati Therapeutics nearly stole the show at Asco despite not actually presenting – a fact that illustrates how low on meaningful data this year's conference was.
Where is the IPO class of 2014-15 now?
A golden age for biotech flotations yielded some spectacular blow-ups, but also saw several groups reward investors with premium-priced takeovers.
